Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1

Conditions

Multiple Myeloma 155Leukemia, Lymphocytic, Chronic, B-Cell 43Lymphoma, Large B-Cell, Diffuse 26Lymphoma 25Lymphoma, Non-Hodgkin 23Lymphoma, Mantle-Cell 23Lymphoma, Follicular 23Leukemia 22Recurrence 21Neoplasms, Plasma Cell 19Myelodysplastic Syndromes 12Lymphoma, B-Cell, Marginal Zone 12Leukemia, Myeloid, Acute 12Waldenstrom Macroglobulinemia 8Smoldering Multiple Myeloma 8Hodgkin Disease 8Prostatic Neoplasms 7Lymphoma, B-Cell 6Lymphoma, T-Cell 5Lymphoma, Large-Cell, Anaplastic 5Hematologic Diseases 5Sezary Syndrome 4Mycosis Fungoides 4Lymphoma, T-Cell, Peripheral 4Leukemia, Myelomonocytic, Chronic 4Immunoblastic Lymphadenopathy 4Anemia 4Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Polycythemia Vera 3Lymphoma, T-Cell, Cutaneous 3

Interventions

pembrolizumab 1lenvatinib 1cediranib 1Sorafenib 1Lenalidomide 1Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Thyroid cancer, Hurthle cell × Lenalidomide × Clear all
NCT01208051 2021-07-15

Cediranib Maleate With or Without Lenalidomide for the Treatment of Thyroid Cancer

National Cancer Institute (NCI)

Phase 1/2 Completed
127 enrolled 18 charts
EndocrineHead & Neck

Thyroid cancer, Hurthle cell, Thyroid Cancer, Papillary, Adenocarcinoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡